165 related articles for article (PubMed ID: 37550816)
1. Pituitary Neuroendocrine Tumor: Is It Benign or Malignant?
Lee CH
Brain Tumor Res Treat; 2023 Jul; 11(3):173-176. PubMed ID: 37550816
[TBL] [Abstract][Full Text] [Related]
2. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Pathological Features of Pit1/SF1 Multilineage Pituitary Neuroendocrine Tumor.
Wang X; Tang H; Bie Z; Wang Y; Yuan R; Zhang Z; Xiong Z; Yang Z; Bi Z; Wang B; Liu P
Neurosurgery; 2024 Jan; ():. PubMed ID: 38289085
[TBL] [Abstract][Full Text] [Related]
4. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract][Full Text] [Related]
5. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
Xie J; Wu ZB
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
[TBL] [Abstract][Full Text] [Related]
6. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
7. Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma.
Tsukamoto T; Miki Y
Jpn J Radiol; 2023 Aug; 41(8):789-806. PubMed ID: 36826759
[TBL] [Abstract][Full Text] [Related]
8. Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.
Wan XY; Chen J; Wang JW; Liu YC; Shu K; Lei T
Curr Med Sci; 2022 Dec; 42(6):1111-1118. PubMed ID: 36544040
[TBL] [Abstract][Full Text] [Related]
9. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
10. [Overview of the New World Health Organization Classification of Pituitary Neuroendocrine Tumors].
Kurosaki M
No Shinkei Geka; 2023 Sep; 51(5):910-916. PubMed ID: 37743343
[TBL] [Abstract][Full Text] [Related]
11. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
[TBL] [Abstract][Full Text] [Related]
12. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
13. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.
Mete O; Wenig BM
Head Neck Pathol; 2022 Mar; 16(1):123-142. PubMed ID: 35312985
[TBL] [Abstract][Full Text] [Related]
14. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal.
Villa C; Baussart B; Assié G; Raverot G; Roncaroli F
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37068095
[TBL] [Abstract][Full Text] [Related]
15. Advances and controversies in the classification and grading of pituitary tumors.
Laws ER; Penn DL; Repetti CS
J Endocrinol Invest; 2019 Feb; 42(2):129-135. PubMed ID: 29858984
[TBL] [Abstract][Full Text] [Related]
16. [Histological Classification and Diagnosis of Sellar/Parasellar Tumors].
Nishioka H
No Shinkei Geka; 2023 Sep; 51(5):789-798. PubMed ID: 37743330
[TBL] [Abstract][Full Text] [Related]
17. Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting.
Sood R; Chatterjee D; Dutta P; Radotra BD
Arch Pathol Lab Med; 2024 Feb; 148(2):178-189. PubMed ID: 37074863
[TBL] [Abstract][Full Text] [Related]
18. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
19. Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET.
Zhang Q; Yao B; Long X; Chen Z; He M; Wu Y; Qiao N; Ma Z; Ye Z; Zhang Y; Yao S; Wang Y; Cheng H; Chen H; Ye H; Wang Y; Li Y; Chen J; Zhang Z; Guo F; Zhao Y
Cell Rep Med; 2023 Feb; 4(2):100934. PubMed ID: 36754052
[TBL] [Abstract][Full Text] [Related]
20. Newer Concepts in the Classification of Pituitary Adenomas.
Sathyakumar R; Chacko G
Neurol India; 2020; 68(Supplement):S7-S12. PubMed ID: 32611886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]